{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:00:24Z","timestamp":1791237624121,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"BeiJing Heart To Heart Foundation","award":["HXXT2022ktyj002"],"award-info":[{"award-number":["HXXT2022ktyj002"]}]},{"name":"Haiyan Foundation of Cancer Hospital Affiliated to Harbin Medical University","award":["JJMs2022-08"],"award-info":[{"award-number":["JJMs2022-08"]}]},{"name":"Institute of Science and Technology, National Health Commission of People's Republic of China","award":["2021HX01408"],"award-info":[{"award-number":["2021HX01408"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11010-024-05168-w","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T06:51:00Z","timestamp":1733381460000},"page":"3097-3116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Salidroside overcomes cisplatin resistance in ovarian cancer via the inhibition of CRNDE-mediated autophagy"],"prefix":"10.1007","volume":"480","author":[{"given":"Ge","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiyasi","family":"Nanding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"5168_CR1","unstructured":"WCRF International. Ovarian cancer statistics. World Cancer Research Fund International. https:\/\/www.wcrf.org\/cancer-trends\/ovarian-cancer-statistics\/. Accessed 23 Mar 2022"},{"key":"5168_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","volume":"41","author":"PM Webb","year":"2017","unstructured":"Webb PM, Jordan SJ (2017) Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 41:3\u201314","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"2","key":"5168_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","volume":"35","author":"C Stewart","year":"2019","unstructured":"Stewart C, Ralyea C, Lockwood S (2019) Ovarian cancer: an integrated review. Semin Oncol Nurs 35(2):151\u2013156","journal-title":"Semin Oncol Nurs"},{"issue":"6","key":"5168_CR4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.hoc.2018.07.005","volume":"32","author":"S Armbruster","year":"2018","unstructured":"Armbruster S, Coleman RL, Rauh-Hain JA (2018) Management and treatment of recurrent epithelial ovarian cancer. Hematol Oncol Clin North Am 32(6):965\u2013982","journal-title":"Hematol Oncol Clin North Am"},{"issue":"Suppl 24","key":"5168_CR5","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1002\/cncr.32500","volume":"125","author":"S Pignata","year":"2019","unstructured":"Pignata S et al (2019) Treatment of recurrent epithelial ovarian cancer. Cancer 125(Suppl 24):4609\u20134615","journal-title":"Cancer"},{"key":"5168_CR6","doi-asserted-by":"publisher","first-page":"114205","DOI":"10.1016\/j.ejmech.2022.114205","volume":"232","author":"M Song","year":"2022","unstructured":"Song M, Cui M, Liu K (2022) Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem 232:114205","journal-title":"Eur J Med Chem"},{"issue":"24","key":"5168_CR7","doi-asserted-by":"publisher","first-page":"17163","DOI":"10.1074\/jbc.M114.558288","volume":"289","author":"J Wang","year":"2014","unstructured":"Wang J, Wu GS (2014) Role of autophagy in cisplatin resistance in ovarian cancer cells. J Biol Chem 289(24):17163\u201317173","journal-title":"J Biol Chem"},{"issue":"1","key":"5168_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/15548627.2016.1239676","volume":"13","author":"M Kim","year":"2017","unstructured":"Kim M et al (2017) GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy. Autophagy 13(1):149\u2013168","journal-title":"Autophagy"},{"issue":"2","key":"5168_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/15548627.2015.1009781","volume":"11","author":"J He","year":"2015","unstructured":"He J et al (2015) Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy. Autophagy 11(2):373\u2013384","journal-title":"Autophagy"},{"issue":"5","key":"5168_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.4161\/auto.7.5.15066","volume":"7","author":"TR O\u2019Donovan","year":"2011","unstructured":"O\u2019Donovan TR, O\u2019Sullivan GC, McKenna SL (2011) Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy 7(5):509\u2013524","journal-title":"Autophagy"},{"issue":"6","key":"5168_CR11","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1074\/jbc.M111.307405","volume":"287","author":"Z Zou","year":"2012","unstructured":"Zou Z et al (2012) MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. J Biol Chem 287(6):4148\u20134156","journal-title":"J Biol Chem"},{"issue":"1","key":"5168_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3892\/mmr.2014.2671","volume":"11","author":"L Bao","year":"2015","unstructured":"Bao L et al (2015) Induction of autophagy contributes to cisplatin resistance in human ovarian cancer cells. Mol Med Rep 11(1):91\u201398","journal-title":"Mol Med Rep"},{"issue":"9","key":"5168_CR13","doi-asserted-by":"publisher","first-page":"e22853","DOI":"10.1002\/jbt.22853","volume":"35","author":"J Ma","year":"2021","unstructured":"Ma J et al (2021) Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1\/PI3K\/mTOR signaling pathway. J Biochem Mol Toxicol 35(9):e22853","journal-title":"J Biochem Mol Toxicol"},{"issue":"30","key":"5168_CR14","doi-asserted-by":"publisher","first-page":"28867","DOI":"10.18632\/oncotarget.4814","volume":"6","author":"C He","year":"2015","unstructured":"He C et al (2015) MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN\/Akt pathway. Oncotarget 6(30):28867\u201328881","journal-title":"Oncotarget"},{"issue":"8","key":"5168_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/kjm2.12696","volume":"39","author":"L Liu","year":"2023","unstructured":"Liu L et al (2023) LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K\/AKT\/mTOR signaling pathway. Kaohsiung J Med Sci 39(8):779\u2013788","journal-title":"Kaohsiung J Med Sci"},{"issue":"1","key":"5168_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41419-021-04474-1","volume":"13","author":"H Huang","year":"2021","unstructured":"Huang H et al (2021) MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer. Cell Death Dis 13(1):13","journal-title":"Cell Death Dis"},{"issue":"7","key":"5168_CR17","doi-asserted-by":"publisher","first-page":"151788","DOI":"10.1016\/j.acthis.2021.151788","volume":"123","author":"C Li","year":"2021","unstructured":"Li C et al (2021) DICER activates autophagy and promotes cisplatin resistance in non-small cell lung cancer by binding with let-7i-5p. Acta Histochem 123(7):151788","journal-title":"Acta Histochem"},{"issue":"4","key":"5168_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1021\/np200555s","volume":"75","author":"EW Qian","year":"2012","unstructured":"Qian EW, Ge DT, Kong SK (2012) Salidroside protects human erythrocytes against hydrogen peroxide-induced apoptosis. J Nat Prod 75(4):531\u2013537","journal-title":"J Nat Prod"},{"issue":"11","key":"5168_CR19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1089\/jmf.2012.2473","volume":"16","author":"B Song","year":"2013","unstructured":"Song B et al (2013) Inhibitory effects of salidroside on nitric oxide and prostaglandin E\u2082 production in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Med Food 16(11):997\u20131003","journal-title":"J Med Food"},{"issue":"5","key":"5168_CR20","first-page":"520","volume":"25","author":"Y Zhang","year":"2013","unstructured":"Zhang Y et al (2013) Effects of salidroside on glioma formation and growth inhibition together with improvement of tumor microenvironment. Chin J Cancer Res 25(5):520\u2013526","journal-title":"Chin J Cancer Res"},{"issue":"10","key":"5168_CR21","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1089\/dna.2010.1183","volume":"30","author":"Y Zhu","year":"2011","unstructured":"Zhu Y et al (2011) Salidroside protects against hydrogen peroxide-induced injury in cardiac H9c2 cells via PI3K-Akt dependent pathway. DNA Cell Biol 30(10):809\u2013819","journal-title":"DNA Cell Biol"},{"issue":"5","key":"5168_CR22","first-page":"6513","volume":"15","author":"G Yu","year":"2018","unstructured":"Yu G et al (2018) Salidroside induces apoptosis in human ovarian cancer SKOV3 and A2780 cells through the p53 signaling pathway. Oncol Lett 15(5):6513\u20136518","journal-title":"Oncol Lett"},{"issue":"3","key":"5168_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bcpt.12906","volume":"122","author":"M Zduriencikova","year":"2018","unstructured":"Zduriencikova M et al (2018) Salidroside, a chemopreventive glycoside, diminishes cytotoxic effect of cisplatin in vitro. Basic Clin Pharmacol Toxicol 122(3):346\u2013354","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"5168_CR24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1021\/acs.jnatprod.1c00950","volume":"85","author":"Q Zeng","year":"2022","unstructured":"Zeng Q et al (2022) Salidroside promotes sensitization to doxorubicin in human cancer cells by affecting the PI3K\/Akt\/HIF signal pathway and inhibiting the expression of tumor-resistance-related proteins. J Nat Prod 85(1):196\u2013204","journal-title":"J Nat Prod"},{"key":"5168_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ebiom.2018.10.069","volume":"38","author":"Y Qin","year":"2018","unstructured":"Qin Y et al (2018) Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1\u03b1 signaling pathway. EBioMedicine 38:25\u201336","journal-title":"EBioMedicine"},{"issue":"1","key":"5168_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/10717544.2020.1754528","volume":"27","author":"Z Zhang","year":"2020","unstructured":"Zhang Z et al (2020) Enhancing the chemotherapy effect of Apatinib on gastric cancer by co-treating with salidroside to reprogram the tumor hypoxia micro-environment and induce cell apoptosis. Drug Deliv 27(1):691\u2013702","journal-title":"Drug Deliv"},{"issue":"1","key":"5168_CR27","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1186\/s12906-017-2046-z","volume":"17","author":"H Li","year":"2017","unstructured":"Li H, Chen C (2017) Inhibition of autophagy enhances synergistic effects of Salidroside and anti-tumor agents against colorectal cancer. BMC Complement Altern Med 17(1):538","journal-title":"BMC Complement Altern Med"},{"issue":"11","key":"5168_CR28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.5483\/BMBRep.2012.45.11.227","volume":"45","author":"R Maruyama","year":"2012","unstructured":"Maruyama R, Suzuki H (2012) Long noncoding RNA involvement in cancer. BMB Rep 45(11):604\u2013611","journal-title":"BMB Rep"},{"issue":"6","key":"5168_CR29","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.3802\/jgo.2022.33.e75","volume":"33","author":"Y Zhu","year":"2022","unstructured":"Zhu Y et al (2022) SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1\/IGF2\/MEK\/ERK axis. J Gynecol Oncol 33(6):e75","journal-title":"J Gynecol Oncol"},{"key":"5168_CR30","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20182101","author":"JT Miao","year":"2019","unstructured":"Miao JT et al (2019) LncRNA ANRIL affects the sensitivity of ovarian cancer to cisplatin via regulation of let-7a\/HMGA2 axis. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20182101"},{"issue":"1","key":"5168_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12935-021-01993-x","volume":"21","author":"Y Wu","year":"2021","unstructured":"Wu Y et al (2021) LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p\/SDC4 axis. Cancer Cell Int 21(1):284","journal-title":"Cancer Cell Int"},{"issue":"4","key":"5168_CR32","doi-asserted-by":"publisher","first-page":"9829","DOI":"10.1080\/21655979.2022.2061181","volume":"13","author":"C Lin","year":"2022","unstructured":"Lin C et al (2022) Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a. Bioengineered 13(4):9829\u20139838","journal-title":"Bioengineered"},{"issue":"5","key":"5168_CR33","doi-asserted-by":"publisher","first-page":"6832","DOI":"10.18632\/aging.202541","volume":"13","author":"Y Ding","year":"2021","unstructured":"Ding Y et al (2021) LncRNA TRPM2-AS promotes ovarian cancer progression and cisplatin resistance by sponging miR-138-5p to release SDC3 mRNA. Aging (Albany NY) 13(5):6832\u20136848","journal-title":"Aging (Albany NY)"},{"key":"5168_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtn.2019.05.007","volume":"17","author":"Z Li","year":"2019","unstructured":"Li Z et al (2019) lncRNA UCA1 mediates resistance to cisplatin by regulating the miR-143\/FOSL2-signaling pathway in ovarian cancer. Mol Ther Nucleic Acids 17:92\u2013101","journal-title":"Mol Ther Nucleic Acids"},{"key":"5168_CR35","doi-asserted-by":"publisher","first-page":"108728","DOI":"10.1016\/j.clim.2021.108728","volume":"227","author":"Y Chen","year":"2021","unstructured":"Chen Y et al (2021) Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2\/STAT3\/PD-L1 pathway. Clin Immunol 227:108728","journal-title":"Clin Immunol"},{"issue":"1","key":"5168_CR36","doi-asserted-by":"publisher","first-page":"14768","DOI":"10.1038\/s41598-020-71153-0","volume":"10","author":"WX Tan","year":"2020","unstructured":"Tan WX et al (2020) Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling. Sci Rep 10(1):14768","journal-title":"Sci Rep"},{"key":"5168_CR37","doi-asserted-by":"publisher","first-page":"7277","DOI":"10.2147\/CMAR.S257311","volume":"12","author":"M Zhu","year":"2020","unstructured":"Zhu M, Yang L, Wang X (2020) NEAT1 Knockdown suppresses the cisplatin resistance in ovarian cancer by regulating miR-770-5p\/PARP1 axis. Cancer Manag Res 12:7277\u20137289","journal-title":"Cancer Manag Res"},{"key":"5168_CR38","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.2147\/CMAR.S295097","volume":"13","author":"X Jiang","year":"2021","unstructured":"Jiang X et al (2021) LNC00115 mediates cisplatin resistance by regulating the miR-7\/ERK signalling pathway in ovarian cancer. Cancer Manag Res 13:3817\u20133826","journal-title":"Cancer Manag Res"},{"issue":"14","key":"5168_CR39","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.3390\/ijms23147737","volume":"23","author":"R Noriega-Rivera","year":"2022","unstructured":"Noriega-Rivera R et al (2022) Upregulation of the Long Noncoding RNA CASC10 promotes cisplatin resistance in high-grade serous ovarian cancer. Int J Mol Sci 23(14):7737","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5168_CR40","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.3802\/jgo.2021.32.e77","volume":"32","author":"L Xiao","year":"2021","unstructured":"Xiao L et al (2021) Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway. J Gynecol Oncol 32(5):e77","journal-title":"J Gynecol Oncol"},{"issue":"7","key":"5168_CR41","first-page":"2506","volume":"12","author":"Y Wu","year":"2019","unstructured":"Wu Y et al (2019) Long non-coding RNA H19 mediates ovarian cancer cell cisplatin-resistance and migration during EMT. Int J Clin Exp Pathol 12(7):2506\u20132515","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"5168_CR42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.yexcr.2018.03.014","volume":"366","author":"L Bai","year":"2018","unstructured":"Bai L et al (2018) Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway. Exp Cell Res 366(2):161\u2013171","journal-title":"Exp Cell Res"},{"key":"5168_CR43","doi-asserted-by":"publisher","first-page":"153957","DOI":"10.1016\/j.prp.2022.153957","volume":"235","author":"J Wu","year":"2022","unstructured":"Wu J et al (2022) CRNDE inducing cisplatin resistance through SRSF1\/TIA1 signaling pathway in ovarian cancer. Pathol Res Pract 235:153957","journal-title":"Pathol Res Pract"},{"issue":"6","key":"5168_CR44","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1089\/dna.2021.0059","volume":"40","author":"H Yang","year":"2021","unstructured":"Yang H et al (2021) YY1-induced lncRNA PART1 enhanced resistance of ovarian cancer cells to cisplatin by regulating miR-512-3p\/CHRAC1 axis. DNA Cell Biol 40(6):821\u2013832","journal-title":"DNA Cell Biol"},{"issue":"4","key":"5168_CR45","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402\u2013408","journal-title":"Methods"},{"key":"5168_CR46","doi-asserted-by":"publisher","first-page":"109726","DOI":"10.1016\/j.biopha.2019.109726","volume":"122","author":"L Rong","year":"2020","unstructured":"Rong L et al (2020) Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K\/Akt\/mTOR pathway. Biomed Pharmacother 122:109726","journal-title":"Biomed Pharmacother"},{"key":"5168_CR47","doi-asserted-by":"publisher","first-page":"114536","DOI":"10.1016\/j.bcp.2021.114536","volume":"190","author":"J Zhao","year":"2021","unstructured":"Zhao J et al (2021) FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer. Biochem Pharmacol 190:114536","journal-title":"Biochem Pharmacol"},{"key":"5168_CR48","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2016.07.015","volume":"66","author":"M Kleppe","year":"2016","unstructured":"Kleppe M et al (2016) The impact of lymph node dissection and adjuvant chemotherapy on survival: A nationwide cohort study of patients with clinical early-stage ovarian cancer. Eur J Cancer 66:83\u201390","journal-title":"Eur J Cancer"},{"issue":"1","key":"5168_CR49","first-page":"143","volume":"27","author":"H Du","year":"2012","unstructured":"Du H et al (2012) Role of autophagy in resistance to oxaliplatin in hepatocellular carcinoma cells. Oncol Rep 27(1):143\u2013150","journal-title":"Oncol Rep"},{"issue":"10","key":"5168_CR50","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/mc.23590","volume":"62","author":"Y Zhou","year":"2023","unstructured":"Zhou Y et al (2023) Baohuoside I inhibits resistance to cisplatin in ovarian cancer cells by suppressing autophagy via downregulating HIF-1\u03b1\/ATG5 axis. Mol Carcinog 62(10):1474\u20131486","journal-title":"Mol Carcinog"},{"issue":"6","key":"5168_CR51","first-page":"1933","volume":"54","author":"S Jiang","year":"2019","unstructured":"Jiang S et al (2019) Icariin enhances the chemosensitivity of cisplatin-resistant ovarian cancer cells by suppressing autophagy via activation of the AKT\/mTOR\/ATG5 pathway. Int J Oncol 54(6):1933\u20131942","journal-title":"Int J Oncol"},{"issue":"6","key":"5168_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14715\/cmb\/2018.64.6.4","volume":"64","author":"Q Liu","year":"2018","unstructured":"Liu Q et al (2018) Luteolin promotes the sensitivity of cisplatin in ovarian cancer by decreasing PRPA1-medicated autophagy. Cell Mol Biol (Noisy-le-grand) 64(6):17\u201322","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"1\u20132","key":"5168_CR53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11010-016-2749-3","volume":"419","author":"WY Yin","year":"2016","unstructured":"Yin WY et al (2016) Salidroside protects cortical neurons against glutamate-induced cytotoxicity by inhibiting autophagy. Mol Cell Biochem 419(1\u20132):53\u201364","journal-title":"Mol Cell Biochem"},{"key":"5168_CR54","doi-asserted-by":"publisher","first-page":"145075","DOI":"10.1016\/j.gene.2020.145075","volume":"767","author":"P Jin","year":"2021","unstructured":"Jin P et al (2021) Salidroside inhibits apoptosis and autophagy of cardiomyocyte by regulation of circular RNA hsa_circ_0000064 in cardiac ischemia-reperfusion injury. Gene 767:145075","journal-title":"Gene"},{"issue":"11","key":"5168_CR55","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1089\/ars.2010.3482","volume":"14","author":"I Tanida","year":"2011","unstructured":"Tanida I (2011) Autophagosome formation and molecular mechanism of autophagy. Antioxid Redox Signal 14(11):2201\u20132214","journal-title":"Antioxid Redox Signal"},{"key":"5168_CR56","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2147\/OTT.S263505","volume":"14","author":"L Ren","year":"2021","unstructured":"Ren L et al (2021) CRNDE contributes cervical cancer progression by regulating miR-4262\/ZEB1 axis. Onco Targets Ther 14:355\u2013366","journal-title":"Onco Targets Ther"},{"issue":"7","key":"5168_CR57","doi-asserted-by":"publisher","first-page":"101088","DOI":"10.1016\/j.tranon.2021.101088","volume":"14","author":"HY Zhu","year":"2021","unstructured":"Zhu HY et al (2021) LncRNA CRNDE promotes the progression and angiogenesis of pancreatic cancer via miR-451a\/CDKN2D axis. Transl Oncol 14(7):101088","journal-title":"Transl Oncol"},{"issue":"2","key":"5168_CR58","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3892\/ol.2022.13190","volume":"23","author":"W Yang","year":"2022","unstructured":"Yang W et al (2022) CRNDE silencing promotes apoptosis and enhances cisplatin sensitivity of colorectal carcinoma cells by inhibiting the Akt\/mTORC1-mediated Warburg effect. Oncol Lett 23(2):70","journal-title":"Oncol Lett"},{"issue":"5","key":"5168_CR59","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s11010-022-04382-8","volume":"477","author":"Q Wang","year":"2022","unstructured":"Wang Q et al (2022) LncRNA CRNDE promotes cell proliferation, migration and invasion of ovarian cancer via miR-423-5p\/FSCN1 axis. Mol Cell Biochem 477(5):1477\u20131488","journal-title":"Mol Cell Biochem"},{"issue":"8","key":"5168_CR60","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/apm.12398","volume":"123","author":"KE Tasioudi","year":"2015","unstructured":"Tasioudi KE et al (2015) Immunohistochemical and molecular analysis of PI3K\/AKT\/mTOR pathway in esophageal carcinoma. APMIS 123(8):639\u2013647","journal-title":"APMIS"},{"issue":"16","key":"5168_CR61","doi-asserted-by":"publisher","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","volume":"65","author":"SY Sun","year":"2005","unstructured":"Sun SY et al (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65(16):7052\u20137058","journal-title":"Cancer Res"},{"issue":"3","key":"5168_CR62","doi-asserted-by":"publisher","first-page":"e22790","DOI":"10.1096\/fj.202200400RR","volume":"37","author":"J Ren","year":"2023","unstructured":"Ren J et al (2023) Annexin A1 induces oxaliplatin resistance of gastric cancer through autophagy by targeting PI3K\/AKT\/mTOR. FASEB J 37(3):e22790","journal-title":"FASEB J"},{"issue":"1","key":"5168_CR63","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12935-021-02153-x","volume":"21","author":"Z Zhao","year":"2021","unstructured":"Zhao Z et al (2021) Knockdown lncRNA CRNDE enhances temozolomide chemosensitivity by regulating autophagy in glioblastoma. Cancer Cell Int 21(1):456","journal-title":"Cancer Cell Int"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-05168-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-024-05168-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-024-05168-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:04:43Z","timestamp":1746176683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-024-05168-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["5168"],"URL":"https:\/\/doi.org\/10.1007\/s11010-024-05168-w","relation":{"references":[{"id-type":"doi","id":"10.1042\/BSR20182101","asserted-by":"subject"}]},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were approved by the Ethical Committee of Harbin Medical University Cancer Hospital and conducted in compliance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}